Luciferase assays revealed that miR-182-5p could bind to RUNDC3A-AS1 and decrease its luciferase activity in the K1 and TPC-1 cell lines, thus antagonized the effect of RUNDC3A-AS1 on the thyroid cancer cell progression. Here, RUNDC3A is linked to thyroid cancer.